Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia

NCT02287558 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT02287558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia
Lead sponsor
The Cleveland Clinic
Phase
Phase 1
Overall status
Completed
Start date
January 27, 2015
Completion date
June 1, 2019
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia, idiopathic vascular ectasia